Cervical atypical glandular cells and false negative HPV testing: A dramatic reality of the wrong test at the right place

European Journal of Gynaecological Oncology

Volumn 35, Issue 2, 2014, Pages 117-120

  Tjalma, W A A ^a   Depuydt, C E ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Department of Molecular Pathology ^*  (Belgium)

Author keywords

Adenocarcinoma; Cervical cancer; Cross protection; E6; E7; False negative; HPV; HPV testing; Human papillomavirus; Integration; L1; Prophylactic vaccination; Screening

Indexed keywords

ADULT; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; CASE REPORT; CERVICAL ATYPICAL GLANDULAR CELL; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOHISTOCHEMISTRY; PAPANICOLAOU TEST; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA; VIRUS LOAD;

ADENOCARCINOMA; ADULT; FALSE NEGATIVE REACTIONS; FEMALE; GENOME, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL LOAD;

EID: 84898984499     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: 10.12892/ejgo24042014     Document Type: Article

References (26)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008". Int. J. Cancer, 2010, 127, 2893.
2. Depuydt C.E., Criel A.M., Benoy I.H., Arbyn M., Vereecken A.J., Bogers J.J.: "Changes in Type-specific Human Papillomavirus Load Predict Progression to Cervical Cancer". J. Cell. Mol. Med., 2012, 16, 3096.
3. Seoud M., Tjalma W.A., Ronsse V.: "Cervical adenocarcinoma: moving towards better prevention". Vaccine, 2011, 29, 9148.
4. Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B. et al.: "HERACLES/SCALE Study Group. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe". Int. J. Cancer, 2013, 132, 854.
5. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B. et al.: "Retrospective International Survey and HPV Time Trends Study Group. Humanpapillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study". Lancet Oncol., 2010, 11, 1048.
6. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S. et al.: "Overview of the European and North American studies on HPV testing in primary cervical cancer screening". Int. J. Cancer, 2006, 119, 1095.
7. Tjalma W.A., Depuydt C.E.: "Don't forget HPV-45 in cervical cancer screening". Am. J. Clin. Pathol., 2012, 137, 161.
8. Tjalma W.A.: "Cervical cancer and prevention by vaccination: results from recent trials". Ann. Oncol., 2006, 17, 217.
9. Trinh X.B., Bogers J.J., Van Marck E.A., Tjalma W.A.: "Treatment policy of neuroendocrine small cell cancer of the cervix". Eur. J. Gynaecol. Oncol., 2004, 25, 40.
10. Bertrand M., Lickrish G.M., Colgan T.J.: "The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment". Am. J. Obstet. Gynecol., 1987, 157, 21.
11. Kusanagi Y., Kojima A., Mikami Y., Kiyokawa T., Sudo T., Yamaguchi S. et al.: "Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype". Am. J. Pathol., 2010, 177, 2169.
12. Bruni L., Diaz M., Castellsagué X., Ferrer E., Bosch F.X., de Sanjosé S.: "Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings". J. Infect. Dis., 2010, 15, 202, 1789.
13. Clifford G., Franceschi S.: "Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix". Int. J. Cancer, 2008, 122, 1684.
14. Tjalma W.A.A.: "Chapter 3: Prophylactic HPV vaccines and their efficacy". Recent Advances in Cervical Cancer; Editor: Iztok Takac 2011; Published by Transworld Research Network, India. 2011, 23.
15. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X. et al.: "HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial". Lancet Oncol., 2012, 13, 89.
16. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P. et al.: "HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial". Lancet Oncol., 2012, 13, 100.
17. Wright T.C. Jr, Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D.: "2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests". Am. J. Obstet. Gynecol., 2007, 197, 346.
18. Wright T.C. Jr, Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D.: "2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ". J. Low Genit. Tract. Dis., 2007, 11, 223.
19. Zhao C., Florea A., Onisko A., Austin R.M.: "Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods". Gynecol. Oncol., 2009, 114, 383.
20. Wright T.C. Jr, Cox J.T., Massad L.S., Carlson J., Twiggs L.B., Wilkinson E.J.: "American Society for Colposcopy and Cervical Pathology. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia". Am. J. Obstet. Gynecol., 2003, 189, 295.
21. Wright T.C. Jr, Cox J.T., Massad L.S., Carlson J., Twiggs L.B., Wilkinson E.J.: "2001 ASCCP-sponsored Consensus Workshop. 2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia". J. Low Genit. Tract. Dis., 2003, 7, 154.
22. Badaracco G., Venuti A., Sedati A., Marcante M.L.: "HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness". J. Med. Virol., 2002, 67, 574.
23. Vinokurova S., Wentzensen N., Kraus I., Klaes R., Driesch C., Melsheimer P. et al.: "Type-dependent integration frequency of human papillomavirus genomes in cervical lesions". Cancer Res., 2008, 68, 307.
24. Qu W., Jiang G., Cruz Y., Chang C.J., Ho G.Y., Klein R.S. et al.: "PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems". J. Clin. Microbiol., 1997, 35, 1304.
25. Morris B.J.: "Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region". Clin. Chem. Lab. Med., 2005, 43, 1171.
26. Depuydt C.E., Boulet G.A., Horvath C.A., Benoy I.H., Vereecken A.J., Bogers J.J.: "Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types". J. Cell. Mol. Med., 2007, 11, 881.